Fig 1: Internal validation of the prognostic signature in TCGA cohort. A KM survival analysis of high-risk and low-risk patients. B ROC curve of TCGA cohort. C Heatmap of GPT and SMS expression. D, E Survival status and risk score of patients
Fig 2: External validation of the prognosis signature in FDEENT cohort. A GPT immunofluorescence staining on TMA. B, C Merged immunofluorescence staining on F-1 T. D Overview of merged immunofluorescence staining on TMA. E, F Merged immunofluorescence staining on F-2 N. G Quantification of the immunofluorescence signals of GPT. H ROC curve of GPT prediction. I Survival analysis of GPT by the KM plotter in LSCC. J ROC curve of risk score (GPT + SMS) prediction. K Survival analysis of risk score (GPT + SMS) by the KM plotter in LSCC
Fig 3: SMS and GPT expression in LSCC patients and cell lines. A GPT is down-regulated in LSCC tissues compared to adjacent normal tissues. B SMS is up-regulated in LSCC tissues compared to adjacent normal tissues. C GPT is down-regulated in LSCC cell lines compared to HuLa-PC, a cell line derived from posterior commissure of the larynx. D SMS is up-regulated in LSCC cell lines compared to HuLa-PC. E Relative expression of GPT in TCGA. F Relative expression of SMS in TCGA
Supplier Page from Abcam for Anti-Alanine Transaminase antibody